That would be the withdrawal of Tysabri, a drug that showed markedly better action against progression of multiple sclerosis than any of its predecessors and also combats “flare-ups” of the condition, but was pulled after reports of a possible link to fatalities from a rare side effect. “Some disappointed patients who benefited from the drug have said they’re willing to take the risk,” but that option’s not open to them. (David Rumbach, “Suffering withdrawal”, South Bend Tribune, May 4; Michael Fumento, “‘Murder on Patients'”, TechCentralStation, May 4).